Skip to main content

30-09-2019 | Urothelial cancer | Video | Article

Researcher comment: IMvigor130 trial of atezolizumab in advanced urothelial cancer

Enrique Grande tells us why the IMvigor130 data, although very promising, are not quite ready for translation to the clinic yet (1:43).

Receive weekly updates on the oncology news that matters

Read the transcript

Back to the WCLC 2019 conference hub

Related topics